Please contact Corporate & Foundation Relations in the Office of Development at devfr@mgh.harvard.edu if you wish to submit a proposal in response to any of these opportunities. Note that proposals are still routed through the standard InfoEd/Research Management process.

Please be aware that any grant that brings in less than 15% in indirect costs (IDC) will need to be supplemented up to the 15% equivalent by existing investigator or departmental sundry funds. Resolution of this issue must occur prior to submitting a proposal. Training fellowships from foundations, public charity, and non-profit organizations are excluded from this minimum IDC requirement.

Have you updated your MGH Researcher profile?
Go to https://researchers.mgh.harvard.edu/ today!

1. Treat FTD (Frontotemporal Degeneration) Fund, Alzheimer’s Drug Discovery Foundation (ADDF)
The Treat FTD fund aims to support programs testing drugs or devices for FTD disorders while building clinical data around novel FTD mechanisms in human disease and corresponding biomarker endpoints in response to treatment. The fund aims to de-risk clinical programs by supporting clinical trials with clear go/no-go criteria and if positive, sufficient data to encourage follow on funding of the approach. Programs will be considered that test novel or repurposed drug candidates or devices in phase 1 or phase 2 clinical trials for FTD disorders, led by academic researchers or biotechnology companies. Both disease-modifying and symptomatic approaches will be accepted.

The RFP seeks to support clinical trials with:
1. biological mechanisms that have a sound scientific rationale for FTD
2. suitable clinical trial designs, that may include features such as basket trials, adaptive study designs or other novel approaches
3. biomarkers that can indicate target engagement and/or downstream pharmacologic effects
4. biomarker endpoints that can provide a deeper understanding of the drug mechanism and disease progression

Although the strongest proposals will contain all of these aspects, any approaches with a sound biological rationale and well justified outcome measures for the patient population will be considered.

Do you want to learn more about identifying external funding opportunities? Please click here to request a research consultation with Amy Robb or see ECOR’s website for information on the Pivot database.
Citizenship: Unrestricted

Award Amount: $500,000-$2 million paid over 1-3 years. Leveraging other sources of funding is encouraged.  
Indirect Costs: None  
LOI Deadline: February 5, 2021  
(Invited) Proposal Deadline: March 19, 2021  
Website: https://www.theaftd.org/for-researchers/treatftd-initiative/

2. Annual Investigator Initiated Research (IIR) Grants, Anesthesia Patient Safety Foundation (APSF)
This program’s objective is to stimulate and fund studies that will clearly improve patient safety and lead to prevention of mortality and morbidity resulting from anesthesia mishaps. Potential areas of research include a wide variety of safety patient topics.

Citizenship: Canada or United States

Award Amount: $150,000 paid over 2 years  
Indirect Costs: 15%  
LOI Deadline: February 18, 2021  
(Invited) Proposal Deadline: Early August 2021  
Website: https://www.apsf.org/grants-and-awards/investigator-initiated-research-iir-grants/

3. COVID-19 Funding Call, British Society for Antimicrobial Chemotherapy (BSAC) COVID!
BSAC is delighted to announce an open call for funding to support grant applications in response to the current coronavirus (COVID-19) public health emergency.

We are especially interested to receive applications (a) from researchers in low-to-middle-income countries, or applications that address aspects of COVID-19 in LMIC communities; (b) that address the impact of COVID-19 on the antimicrobial resistance and antimicrobial stewardship agenda.

Citizenship: Unrestricted

Award Amount: $25,000-$100,000  
Indirect Costs: None  
LOI Deadline: January 18, 2021  
(Invited) Application Deadline: April 9, 2021  
Website: http://www.bsac.org.uk/funding/

4. Basic Research Grants Program and Fellowships, Hereditary Disease Foundation
The Hereditary Disease Foundation provides funding for research that advances the discovery and development of treatments for Huntington’s disease and other brain disorders. We are
passionate about finding and funding the most innovative, creative and paradigm-changing research possible. The data generated with HDF funding often allows researchers to get initial findings that help them apply successfully for larger, long-term funding from other funding agencies, including the National Institutes of Health.

The Foundation’s current focus is on 1) modifier studies - on DNA repair pathways, protein degradation and other modifiers of phenotype and age of onset; 2) mechanisms of HD neurodegeneration; 3) biomarkers of disease progression; and 4) therapy for HD-induced neurodegeneration.

Types of Funding
The Basic Research Grants Program: Supports projects contributing to identifying and understanding the fundamental defects in Huntington’s disease.

Postdoctoral Fellowships: These postdoctoral fellowships are intended to cultivate interest in Huntington’s disease research by bright young scientists. Fellowships are granted to those who possess imagination, rigor, creativity and spirit to push forward toward a cure for HD and ensure that these discoveries can be applied to other brain diseases.

Citizenship: Unspecified

Award Amount:
- Research Grants: $75,000 for 1 year
- Postdoctoral Fellowships: The Hereditary Disease Foundation will provide salary support based on the NIH Guidelines PER YEAR for the two years as well as additional funding up to $10,000 per year for supplies, equipment and benefits.

Indirect Costs: None
LOI Deadline: February 1, 2021
Application Deadline: April 16, 2021
Website: http://www.hdfoundation.org/funding-the-future-2/

5. Fellowship Awards, Jane Coffin Childs Memorial Fund for Medical Research (JCC Fund)
The Fund was established in 1937 for the purpose of supporting research into the causes and treatment of cancer. The Fund has taken a broad approach to the study of cell growth and development, emphasizing the study of the basic biology and chemistry of the underlying processes. The Fund has increasingly focused its resources on the funding of postdoctoral Fellowships, supporting Fellows selected by its Board of Scientific Advisers from among the best young scientists at what is often a critical stage in their careers.

Eligibility requirements (partial list):
- Postdoctoral applicants should have no more than one year of postdoctoral research experience at the time of the deadline for submitting applications.
• PhD degree must not have been conferred more than 18 months prior to the deadline date.
• MD degree should not have been conferred more than three years before deadline date of application.
• PhD candidates that do not have their degree at time of application deadline are eligible to apply. If awarded, the applicant’s PhD degree must be conferred prior to the start of the Fellowship.

Citizenship: Unrestricted

Award Amount: $162,000 paid over 3 years
Indirect Costs: None
Application Deadline: February 1, 2021
Website: http://www.jccfund.org/fellowship-information/

The Leukemia Research Foundation exclusively funds New Investigators - individuals beginning to establish their own laboratories that are no longer under the tutelage of a senior scientist mentor. It is difficult for them to get the level of funding they need at this critical point in their careers.

The Leukemia Research Foundation is unique in the level of support it provides to highly promising scientists in this absolutely critical research niche. Providing one year grants to selected New Investigator researchers allows innovative scientists to act on their ideas, and try new procedures and experiments that will hopefully lead to significant breakthroughs. The Leukemia Research Foundation funds the research of scientists that are from independent labs, not the labs of pharmaceutical companies.

The criterion on which the panel bases their assessment includes three basic points:
1. Innovation - the innovation a proposal offers, discerning whether the findings will contribute to leukemia, lymphoma, multiple myeloma, and MDS research.
2. Mission - what effect the study may have on how blood cancers are detected, diagnosed and treated.
3. Training/Environment - training and preparedness of the applicant & their research setting.

Citizenship: Unrestricted

Award Amount: $100,000 for 1 year
Indirect Costs: None
LOI Deadline: February 5, 2021
(Invited) Proposal Deadline: April 5, 2021
Website: https://allbloodcancers.org/guidelines/
7. Research Grants, Scleroderma Research Foundation (SRF)

The Scleroderma Research Foundation (SRF) funds research aimed at understanding the pathogenesis of scleroderma and promoting the design, development, and pilot-testing of hypothesis-driven, innovative, therapeutic approaches.

Intended for Established Investigators and New Faculty members, the SRF has several funding mechanisms tailored to projects of varying scope that are aimed at understanding the Molecular Pathogenesis and New Interventions in Scleroderma Research. With few exceptions, funding support from the SRF may not be used for administrative overhead, indirect expenses, or other institutional charges.

Citizenship: Unrestricted

Award Amount:
- Investigator-Initiated Research Grants (SRF01): Up to $600,000 paid over 3 years
- Exploratory/Developmental grants (SRF02): Up to $150,000 paid over 2 years
- New Faculty Grants (SRF03): Up to $150,000 paid over 2 years

Indirect Costs: None

Application Deadline: January 10, 2021
Website: https://srfcure.org/apply-for-a-grant/